June 1, 2011 -- Putnam Associates, a Boston-based strategy consulting firm serving the biotechnology and pharmaceutical industries globally, is pleased to announce that Eric Auger, Partner, and Matthew Riordan, Senior Manager, recently participated in Eye for Pharma’s Market Access and Launch Excellence Summit 2011, where Matt spoke on the topic, “Mitigating the Risks in Risk Sharing Agreements.” The conference was held on May 16-17, 2011 in Berlin, Germany.
A description of the session includes:
• Innovative, risk-sharing access agreements are becoming commonplace in launching new drugs in key European markets
• While these agreements offer an avenue to find common ground with payers, their complexity can introduce a range of new risks for biopharmaceutical manufacturers to manage
• The session reviewed the types of agreements being executed and the manufacturer risks they introduce, and reviewed case studies illustrating potential risk mitigation strategies
The presentation can be downloaded at http://www.putassoc.com/putnam53111.pdf.
Mr. Auger heads Putnam’s Global Pricing and Reimbursement practice and is a leader in Putnam’s US and Global Franchise Strategy practices. Having joined Putnam Associates in 1996 and become a Partner in 2005, he brings 16 years of strategy consulting experience in the pharmaceutical, biotechnology, and life sciences areas, including extensive engagements in both US and global markets. He has helped develop and revitalize pricing and reimbursement platforms (value propositions and economic analyses) for a range of high-profile products in pre-launch, mid-lifecycle, and LOE phases. His therapeutic area expertise spans a wide range of specialty categories including Infectious Disease, Vaccines, Women’s Health, Immunology, Oncology, CNS, GI, and CV. Prior to joining Putnam, Eric began his strategy consulting career at Bain & Company in Boston. He holds a BA in Economics from Providence College, an MA in International Relations from Boston University, and completed post-graduate studies at MIT’s Sloan School of Management.
Mr. Riordan is a leader in Putnam’s Global Pricing and Reimbursement and US and Global Franchise Strategy practices. He joined Putnam in 2003 and has worked extensively in oncology and other specialty categories managing therapeutic area strategies, product growth strategies, and pricing and reimbursement strategies. Prior to joining Putnam, Matt worked for a retirement policy think tank conducting analysis on the drawdown of Social Security and Medicare trust funds. He graduated magna cum laude, Phi Beta Kappa from Boston College with a degree in Economics, and earned his MBA from the Yale School of Management in the focused Healthcare MBA Program.
Putnam Associates (www.putassoc.com) is a strategy consulting firm headquartered in Boston, founded in 1988, advising the pharmaceutical, biotechnology, diagnostics, and medical device industries on a global basis. Over two decades of experience and focus in their industries enable Putnam to create significant value for their clients. Creative and disciplined strategy development processes blend with deep market knowledge for one purpose: to help their clients succeed. The company’s partnership includes: Kevin J. Gorman, Managing Partner (BA, Boston College; MBA, Harvard Business School); Richard J. Tinsley, Partner (BA, Wharton School, University of Pennsylvania; MA, Stanford University; MBA, Stanford University Graduate School of Business); John A. Gordon, Partner (BA, Tufts University; MBA, Harvard Business School); Eric C. Auger, Partner (BA, Providence College; MA, Boston University); and Domenick Bertelli, Partner (AB, Harvard University; MBA, MIT Sloan School of Management).
